CARISMA THERAPEUTICS TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCE IN JANUARY

January 27, 2021

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that Steven Kelly, the President & CEO, will present at a virtual investor conference in January.

  • Solebury Trout Winter Private Company Showcase
    January 29, 2021
    Presentations will be available Friday at the following link https://troutaccess.com/investor.php/participatingcompanies/details/company_hash/b45fdd7041c1afe62f350f48a3d42db3/conference_hash/e1e5eb88c06de1cbd628c42a940c8290

About CARISMA Therapeutics Inc.
CARISMA Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.

For more information, please visit www.carismatx.com